<DOC>
	<DOCNO>NCT01597492</DOCNO>
	<brief_summary>The purpose study assess impact belimumab immune response pneumococcal vaccine subject Systemic Lupus Erythematosus ( SLE ) .</brief_summary>
	<brief_title>A Study Evaluate Effect Belimumab Vaccine Responses Subjects With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description>All patient study receive belimumab plus standard therapy SLE vaccination pneumococcus . Patients randomize receive pneumococcal vaccination either 4 week prior ( early vaccination group ) 24 week ( late vaccination group ) first belimumab dose . Vaccine response assess 4 week vaccine administration .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Key Clinical diagnosis SLE American College Rheumatology ( ACR ) criterion . Active SLE disease . Autoantibodypositive . Have antibody titer &gt; 1.0 microgram ( mcg ) /mL 9 23 serotypes present pneumococcal vaccine . Have ability understand requirement study , provide write informed consent , comply study protocol procedure . Key Pregnant nursing . Have receive prior treatment belimumab . Have receive live vaccine within past 30 day . Have receive pneumococcal vaccination past 5 year . Have history severe allergic reaction vaccine , contrast agent ( use xrays CT scan ) , biological medicine . Have require management infection infection keep come back within past 60 day . Hepatitis B : Serologic evidence Hepatitis B ( HB ) infection base result test HB surface antigen ( HBsAg ) antiHB core antibody ( antiHBc ) : Subjects positive HBsAg exclude . Subjects negative HBsAg positive antiHBc , regardless antiHBs antibody status , exclude . Hepatitis C : Positive test Hepatitis C antibody . Known human immunodeficiency virus ( HIV ) infection . Have current drug alcohol abuse dependence . Have Grade 3/4 immunoglobulin ( Ig ) G deficiency ( IgG level &lt; 400 milligram [ mg ] / deciliter [ dL ] ) IgA deficiency ( IgA level &lt; 10 mg/dL ) . Subjects evidence serious suicide risk include history suicidal behavior last 6 month and/or suicidal ideation intent act last 2 month investigator 's judgment , pose significant suicide risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Antibodies</keyword>
	<keyword>Vaccines</keyword>
	<keyword>SLE</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Biological Therapy</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Pneumococcal Vaccines</keyword>
	<keyword>Lupus</keyword>
	<keyword>Immunoglobulins</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Belimumab</keyword>
	<keyword>Biological Agents</keyword>
	<keyword>Immunization</keyword>
</DOC>